Icon in Diabetes Testing Accuracy Joins Push for WaveSense, Inc. Technology

SALEM, N.H., June 22 /PRNewswire/ -- AgaMatrix, the developers of WaveSense technology, which enables high accuracy blood glucose monitoring (BGM) products for the diabetes market, announced today that Barry Ginsberg, MD, PhD, an iconic figure in diabetes and BGM technology, has joined its Medical Board of Advisors.

Ginsberg co-authored a seminal paper in 2000 that established the Parkes- Ginsberg Error Grid, which has since become an internationally accepted method to evaluate clinical data from blood glucose meters. Ginsberg spent the last 17 years as the VP of Worldwide Medical Affairs at BD Medical leading the medical affairs of their diabetes program. Prior to working at BD, he was a professor of internal medicine and biochemistry at the University of Iowa. During his tenure, Ginsberg was a principal investigator of the Diabetes Control and Complications Trial (DCCT). This landmark study showed that keeping blood glucose levels as close to normal as possible slowed the onset and progression of eye, kidney, and nerve diseases caused by diabetes. At the time, the DCCT was the largest and most comprehensive diabetes study ever conducted.

"Accuracy is the biggest deficiency in today's home BGM systems and we've seen that tighter control of blood glucose in people with diabetes has been proven to decrease the risk of medical complications," said Dr. Ginsberg. "WaveSense is the only technology today that can truly enable high accuracy home BGM's, so naturally I'm extremely encouraged by the new standard of accuracy which WaveSense establishes."

Currently, major regulatory bodies require that 95% of the results (> 75 mg/dl) from a BGM be within 20% of an accepted laboratory standard, or +/- 20% accuracy. The American Diabetes Association (ADA) has been actively pushing for more stringent requirements for the last 20 years. Their 1993 Consensus Statement's recommendation is for +/-5% accuracy. BGM makers have been technically unable to meet this goal. Clinical results have shown that WaveSense had 95% of results within the +/-10% accuracy target.

Meg Wiley, RN, BSN, Head of Clinical Affairs at AgaMatrix, said, "Dr. Ginsberg's involvement in AgaMatrix is a testament to the accuracy of WaveSense and to the fact that WaveSense fills an industry void for better accuracy in home glucose monitoring."

About AgaMatrix

AgaMatrix is a technology company headquartered in Salem, New Hampshire that develops and manufactures next generation blood glucose monitoring (BGM) products for the diabetes market. The Company's proprietary WaveSense biosensor technologies (http://www.wavesense.info) enable significantly higher accuracy glucose sensing. Current products include a line of meter and strip systems and a blood glucose data management software system.

AgaMatrix, WaveSense, and the AgaMatrix logo are trademarks of AgaMatrix, Inc.

CONTACT: Anne Gvazdauskas of AgaMatrix, Inc., +1-603-328-6081,media@agamatrix.com

Web site: http://www.agamatrix.com//